Jupiter Neurosciences Launches Consumer Longevity Line Nugevia Using Patented JOTROL Technology
TL;DR
Jupiter Neurosciences' patented JOTROL formulation delivers 8-10 times higher resveratrol levels than competitors with no GI side effects, creating a therapeutic advantage through 2036.
JOTROL achieves therapeutic plasma concentrations over 250 ng/mL through a reformulated resveratrol that requires one-tenth the dose of conventional products without gastrointestinal effects.
Jupiter Neurosciences' products improve brain health, longevity, and cellular function, potentially enhancing quality of life for those with neurodegenerative conditions and aging populations.
JOTROL provides the resveratrol equivalent of 10,000 bottles of red wine daily through just two capsules, revolutionizing antioxidant and anti-inflammatory supplementation.
Found this article helpful?
Share it with your network and spread the knowledge!
Jupiter Neurosciences Inc. has launched Nugevia, a direct-to-consumer product line utilizing its patented JOTROL technology to deliver therapeutic levels of resveratrol for longevity and brain health applications. The company's leadership emphasized the scientific breakthrough behind JOTROL, which achieves blood plasma levels 8-10 times higher than conventional resveratrol with one-tenth the dose and no gastrointestinal side effects.
Christer Rosen, Chairman and CEO, explained the formulation's significance during an interview, stating that existing products fail to deliver adequate resveratrol concentrations to the bloodstream. JOTROL's patented technology enables therapeutic benefits without requiring excessive consumption, addressing a longstanding challenge in resveratrol supplementation. The formulation activates PARP-1, a protein crucial for DNA repair and stress response, while providing antioxidant, anti-inflammatory, cardiovascular, and cognitive benefits.
The company is leveraging this technology for both pharmaceutical and consumer markets. While developing JOTROL for central nervous system disorders including Alzheimer's and Parkinson's disease through clinical trials, Jupiter Neurosciences recognized an opportunity in the growing longevity market. Alison Silva, President and CBO, noted that many companies make claims without clinical proof, whereas Jupiter Neurosciences possesses demonstrated efficacy data.
Nugevia's initial three formulations target specific health areas: Nugevia GLO focuses on skin health through cellular defense and collagen support, Nugevia PWR addresses mitochondrial health for energy and recovery, and Nugevia MND enhances cognitive function and brain health. All products will be available through direct-to-consumer channels beginning in September.
Revenue from the Nugevia line is expected to materialize progressively, with more significant impact anticipated as brand ambassadors and key opinion leaders promote the products. Professional golfer Annika Sörenstam has been announced as the first brand ambassador, with additional partnerships forthcoming. Rosen addressed market challenges, including short seller pressure, expressing confidence that product delivery will ultimately drive shareholder value. The company's approach combines scientific innovation with commercial strategy, positioning JOTROL as a transformative technology in both therapeutic and consumer health markets.
Curated from NewMediaWire
